Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-06 6:02 pm Purchase | 2025-02-27 | 13G | Tyra Biosciences, Inc. TYRA | TCG Crossover GP I LLC | 2,898,103 5.700% | 2,898,103 (New Position) | Filing History |
| 2025-02-14 4:44 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I LLC | 0 0.000% | -1,555,118 (Position Closed) | Filing History |
| 2025-02-14 4:23 pm Purchase | 2024-12-31 | 13G | Upstream Bio, Inc. UPB | TCG Crossover GP I LLC | 2,801,763 5.200% | 2,801,763 (New Position) | Filing History |
| 2024-11-13 4:25 pm Sale | 2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I LLC | 1,555,118 5.200% | -1,123,091 (-41.93%) | Filing History |
| 2024-04-19 7:09 pm Purchase | 2024-04-11 | 13G | ABIVAX SA ABVX | TCG Crossover GP I LLC | 6,056,596 9.600% | 6,056,596 (New Position) | Filing History |
| 2024-04-01 4:14 pm Sale | 2024-03-28 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I LLC | 1,345,826 3.200% | -1,355,014 (-50.17%) | Filing History |
| 2024-02-20 4:49 pm Sale | 2024-02-07 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I LLC | 2,700,840 6.520% | -707,241 (-20.75%) | Filing History |
| 2024-02-13 4:27 pm Sale | 2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | TCG Crossover GP I LLC | 0 0.000% | -5,905,400 (Position Closed) | Filing History |
| 2024-02-09 4:31 pm Purchase | 2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON | TCG Crossover GP I LLC | 3,570,206 5.400% | 3,570,206 (New Position) | Filing History |
| 2024-02-09 4:29 pm Purchase | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I LLC | 2,678,209 9.000% | 1,388,889 (+107.72%) | Filing History |
| 2024-02-09 4:28 pm Purchase | 2023-06-16 | 13G | Aerovate Therapeutics, Inc. AVTE | TCG Crossover GP I LLC | 62,894 8.000% | 62,894 (New Position) | Filing History |
| 2024-02-09 4:24 pm Sale | 2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA | TCG Crossover GP I LLC | 2,912,861 1.600% | -8,198,250 (-73.78%) | Filing History |
| 2024-02-09 4:22 pm Purchase | 2024-01-29 | 13G | Tourmaline Bio, Inc. TRML | TCG Crossover GP I LLC | 1,477,593 5.900% | 1,477,593 (New Position) | Filing History |
| 2024-02-09 4:22 pm Purchase | 2023-12-31 | 13G | Cogent Biosciences, Inc. COGT | TCG Crossover GP I LLC | 5,631,042 6.500% | 2,000,000 (+55.08%) | Filing History |
| 2023-08-28 4:08 pm Purchase | 2023-08-18 | 13G | COMPASS Pathways plc CMPS | TCG Crossover GP I LLC | 6,437,497 9.900% | 6,437,497 (New Position) | Filing History |
| 2023-08-25 4:22 pm Purchase | 2023-08-16 | 13G | Taysha Gene Therapies, Inc. TSHA | TCG Crossover GP I LLC | 11,111,111 5.900% | 11,111,111 (New Position) | Filing History |
| 2023-07-25 4:19 pm Purchase | 2023-06-26 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I LLC | 1,289,320 6.600% | 1,289,320 (New Position) | Filing History |
| 2023-07-25 4:18 pm Purchase | 2023-05-25 | 13G | Icosavax, Inc. ICVX | TCG Crossover GP I LLC | 3,703,704 7.500% | 3,703,704 (New Position) | Filing History |
| 2023-07-25 4:17 pm Purchase | 2023-07-17 | 13G | Savara Inc. SVRA | TCG Crossover GP I LLC | 10,000,000 7.400% | 10,000,000 (New Position) | Filing History |
| 2023-02-14 2:23 pm Purchase | 2022-12-31 | 13G | Cogent Biosciences, Inc. COGT | TCG Crossover GP I LLC | 3,631,042 5.200% | 3,631,042 (New Position) | Filing History |